Ronald H. Goldstein, MD
Voluntary Professor
Boston University Chobanian & Avedisian School of Medicine
Pulmonary, Allergy, Sleep & Critical Care Medicine

MD, SUNY Downstate Medical Center
BS, University of Wisconsin Madison

Our laboratory is exploring the regulation of the alveolar matrix during the development of early emphysema and fibrosis. The loss of matrix substances results in emphysema whereas the excessive deposition of matrix substances results in pulmonary fibrosis. Employing the techniques of cellular and molecular biology, we are developing methods to modulating the levels of collagen, elastin and other key matrix substances in the alveolar wall. These approaches are studied in wild type and transgenic murine models of emphysema and fibrosis.

We have extensive experience in the diagnosis and management of individuals with pulmonary fibrosis. In human studies, our clinical experimental interest involves the use of novel substances to treat idiopathic pulmonary fibrosis (IPF). We participate in several clinical studies to evaluate the efficacy of these agents in the pathogenesis of IPF.

Research special interests include: Pulmonary Matrix Biology related to Pulmonary Fibrosis and Emphysema

Clinical special interests include: Pulmonary Fibrosis

Voluntary Research Assistant Professor
Boston University Chobanian & Avedisian School of Medicine
Biochemistry & Cell Biology

Boston University
Pulmonary Center

Graduate Faculty (Primary Mentor of Grad Students)
Boston University Chobanian & Avedisian School of Medicine, Graduate Medical Sciences

VA Boston Healthcare System

Pre-Clinical Assessment of the Effect of B2-Agonist Isomers of Formoterol on the Development of Emphysema
01/01/2008 - 09/30/2009 (PI)
Sepracor, Inc.

Regulation of Collagen Formation in Pulmonary Fibrosis
08/01/2002 - 07/31/2007 (PI)
NIH/National Heart, Lung, and Blood Institute
5 R01 HL70182 04

The Role of CTGF in Subepithelial Fibrosis in Asthma
07/01/2000 - 06/30/2006 (Dept Sponsor)
NIH/National Heart, Lung, and Blood Institute
5 K08 HL04232 05

Clinical Centers for Feasibility Studies of Retinoid Treatment in Emphysema (FORTE)
09/30/1999 - 12/31/2004 (Co-PI)
PI: George T. O'Connor, MD
NIH/National Heart, Lung, and Blood Institute
N01 HR 96141

Effect of IL-l and TNF-A on Elastin Production in COPD
09/29/2000 - 08/31/2004 (PI)
NIH/National Heart, Lung, and Blood Institute
5 R01 HL66547 04

SCOR in Pathobiology of Fibrotic Lung Disease
12/01/1996 - 06/30/2002 (PI)
NIH/National Heart, Lung, and Blood Institute
5 P50 HL56386 05


Yr Title Project-Sub Proj Pubs
2019 Tadalafil for Pulmonary Hypertension Associated with Chronic Lung Disease 5I01CX000908-06 1
2017 Tadalafil for Pulmonary Hypertension Associated with Chronic Lung Disease 5I01CX000908-05 1
2016 Tadalafil for Pulmonary Hypertension Associated with Chronic Lung Disease 5I01CX000908-04 1
2015 Tadalafil for Pulmonary Hypertension Associated with Chronic Lung Disease 5I01CX000908-03 1
2014 Tadalafil for Pulmonary Hypertension Associated with Chronic Lung Disease 5I01CX000908-02 1
2013 Tadalafil for Pulmonary Hypertension Associated with Chronic Lung Disease 1I01CX000908-01 1
2005 Regulation of Collagen Formation in Pulmonary Fibrosis 5R01HL070182-04 4
2005 IL -1 and TNF alpha in the development of COPD 5P01HL046902-14-8 80
2004 Regulation of Collagen Formation in Pulmonary Fibrosis 5R01HL070182-03 4
2003 Regulation of Collagen Formation in Pulmonary Fibrosis 5R01HL070182-02 4
Showing 10 of 37 results. Show All Results

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Johnson SW, Finlay L, Mathai SC, Goldstein RH, Maron BA. Real-world use of inhaled treprostinil for lung disease-pulmonary hypertension: A protocol for patient evaluation and prescribing. Pulm Circ. 2022 Jul; 12(3):e12126.View Related Profiles. PMID: 36092795; PMCID: PMC9450844; DOI: 10.1002/pul2.12126;
  2. Maron BA, Choudhary G, Goldstein RL, Garshick E, Jankowich M, Tucker TJS, LaCerda KA, Hattler B, Dempsey EC, Sadikot RT, Shapiro S, Rounds SI, Goldstein RH. Tadalafil for veterans with chronic obstructive pulmonary disease-pulmonary hypertension: A multicenter, placebo-controlled randomized trial. Pulm Circ. 2022 Jan; 12(1):e12043.View Related Profiles. PMID: 35506072; PMCID: PMC9053004; DOI: 10.1002/pul2.12043;
  3. Clark K, Goldstein R, Maron B, Breu AC. A Veteran Presenting With Chronic Progressive Dyspnea on Exertion. Fed Pract. 2020 Nov; 37(11):522-526.View Related Profiles. PMID: 33328718; PMCID: PMC7735459; DOI: 10.12788/fp.0066;
  4. Maron BA, Brittan EL, Hess E, Waldo SW, Barón AE, Huang S, Goldstein RH, Assad T, Wertheim BM, Alba GA, Leopold JA, Olschewski H, Galiè N, Simonneau G, Kovacs G, Tedford RJ, Humbert M, Choudhary G. Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study. Lancet Respir Med. 2020 09; 8(9):873-884.View Related Profiles. PMID: 32730752; PMCID: PMC8219057; DOI: 10.1016/S2213-2600(20)30317-9;
  5. Maron BA, Hess E, Maddox TM, Opotowsky AR, Tedford RJ, Lahm T, Joynt KE, Kass DJ, Stephens T, Stanislawski MA, Swenson ER, Goldstein RH, Leopold JA, Zamanian RT, Elwing JM, Plomondon ME, Grunwald GK, Barón AE, Rumsfeld JS, Choudhary G. Association of Borderline Pulmonary Hypertension With Mortality and Hospitalization in a Large Patient Cohort: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program. Circulation. 2016 Mar 29; 133(13):1240-8.View Related Profiles. PMID: 26873944; PMCID: PMC4811678; DOI: 10.1161/CIRCULATIONAHA.115.020207;
  6. Berry NC, Manyoo A, Oldham WM, Stephens TE, Goldstein RH, Waxman AB, Tracy JA, Leary PJ, Leopold JA, Kinlay S, Opotowsky AR, Systrom DM, Maron BA. Protocol for exercise hemodynamic assessment: performing an invasive cardiopulmonary exercise test in clinical practice. Pulm Circ. 2015 Dec; 5(4):610-8.View Related Profiles. PMID: 26697168; PMCID: PMC4671735; DOI: 10.1086/683815;
  7. Maron BA, Goldstein RH, Rounds SI, Shapiro S, Jankowich M, Garshick E, Moy ML, Gagnon D, Choudhary G. Study design and rationale for investigating phosphodiesterase type 5 inhibition for the treatment of pulmonary hypertension due to chronic obstructive lung disease: the TADA-PHiLD (TADAlafil for Pulmonary Hypertension associated with chronic obstructive Lung Disease) trial. Pulm Circ. 2013 Dec; 3(4):889-97.View Related Profiles. PMID: 25006405; PMCID: PMC4070834; DOI: 10.1086/674759;
  8. Golan-Gerstl R, Wallach-Dayan SB, Zisman P, Cardoso WV, Goldstein RH, Breuer R. Cellular FLICE-like inhibitory protein deviates myofibroblast fas-induced apoptosis toward proliferation during lung fibrosis. Am J Respir Cell Mol Biol. 2012 Sep; 47(3):271-9.View Related Profiles. PMID: 22582174; PMCID: PMC5460908; DOI: 10.1165/rcmb.2010-0284RC;
  9. Yu J, Taylor L, Rich C, Toselli P, Stone P, Green D, Warburton R, Hill N, Goldstein R, Polgar P. Transgenic expression of an altered angiotensin type I AT1 receptor resulting in marked modulation of vascular type I collagen. J Cell Physiol. 2012 May; 227(5):2013-21.View Related Profiles. PMID: 21751211; PMCID: PMC3247653; DOI: 10.1002/jcp.22929;
  10. Brooks WW, Shen S, Conrad CH, Goldstein RH, Deng LL, Bing OH. Transcriptional changes associated with recovery from heart failure in the SHR. J Mol Cell Cardiol. 2010 Sep; 49(3):390-401.View Related Profiles. PMID: 20547165; DOI: 10.1016/j.yjmcc.2010.06.002;
Showing 10 of 93 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 90 publications over 31 distinct years, with a maximum of 7 publications in 1996


In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Pulmonary Fibrosis
Contact for Mentoring:

72 E. Concord St Housman (R)
Boston MA 02118
Google Map

Goldstein's Networks
Click the "See All" links for more information and interactive visualizations
Similar People
Same Department